RecruitingNCT06626360

Screening for Malnutrition in Obese Patients

SCreening fOr Malnutrition and Obesity in Patients With COVID-19 and Other Diseases


Sponsor

HAN University of Applied Sciences

Enrollment

2,000 participants

Start Date

Oct 2, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

More than half of the Dutch population is overweight or obese, which is associated with an increased risk of COVID-19 and worse outcomes during a COVID-19 infection. In addition, malnutrition and loss of muscle mass are often reported with COVID-19, as well as with cancer and other diseases. Malnutrition and overweight or obesity can coexist, even within the same individual. It is still unclear which mechanisms contribute to the worse outcomes of COVID-19 and other diseases in case of overweight, malnutrition, and a combination of both. The aim of this study is to identify which parameters are associated with worse disease outcomes through literature research and database research (COVID-19 and cancer, more than 150.000 participants). In addition, a clinical study will be conducted aiming to develop a simple screening tool for the recognition of the coexistence of malnutrition and overweight or obesity in clinical practice.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age 18 years or older
  • Overweight (BMI of 25 kg/m² or higher)

Exclusion Criteria4

  • Physically or mentally unable to participate.
  • Severe cognitive disorder or severe emotional instability, as assessed by the attending nurse or physician.
  • Insufficient proficiency in the Dutch language to express themselves properly and no interpreter or assistant to help.
  • Patient resides in a nursing or care home.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(3)

OLVG

Amsterdam, Netherlands

Ziekenhuis Gelderse Vallei

Ede, Netherlands

ErasmusMC

Rotterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06626360


Related Trials